Yu Ying Yau

Controlled study of citrate effects and response to IV calcium administration during allogeneic peripheral blood progenitor cell donation

BACKGROUND: Leukapheresis procedures are generally performed at citrate anticoagulation rates extrapolated from shorter plateletpheresis procedures. However, neither the metabolic effects nor the management of associated symptoms have been critically evaluated during leukapheresis in healthy donors.

Administration of G–CSF plus dexamethasone producesgreater granulocyte concentrate yields while causing nomore donor toxicity than G–CSF alone

BACKGROUND: G–CSF with or without dexamethasone is becoming the standard agent for mobilizing granulocytes for transfusion. The purpose of this study was to determine if the toxicities of G–CSF with or without dexamethasone are offset by greater collection yields and to define the minimum interval that should separate sequential collections.

Analysis of PBPC cell yields during large‐volume leukapheresis of subjects with a poor mobilization response to filgrastim

BACKGROUND: The circulating CD34 count is a reliable predictor of peripheral blood progenitor cell (PBPC) yields in subjects with a vigorous mobilization response to G‐CSF, however, the value of this parameter in poor mobilizers is uncharacterized.

Ascertainment of iron deficiency and depletion in blood donors through screening questions for pica and restless legs syndrome

Pica and restless legs syndrome (RLS) are associated with iron depletion and deficiency. The presence of pica and RLS was prospectively assessed in blood donors.

Hemochromatosis subjects as allogeneic blood donors: a prospective study

BACKGROUND:  Persons with hemochromatosis constitute a plentiful and willing source of blood for transfusion. A program was established and evaluated for treating persons with hemochromatosis in a donor center and making their blood available for transfusion.

Iron replacement therapy in the routine management of blood donors

BACKGROUND: Iron depletion or deficiency in blood donors frequently results in deferrals for low hemoglobin (Hb), yet blood centers remain reluctant to dispense iron replacement therapy to donors.

Pediatric large-volume leukapheresis: a single institution experience with heparin versus citrate-based anticoagulant regimens.

BACKGROUND: Anticoagulant‐associated toxicity may exert significant effects on the safety and efficacy of large‐volume leukapheresis (LVL) in children, however, few studies specifically address management of this issue.

Randomized placebo-controlled study of oral calcium carbonate supplementation in plateletpheresis: II. Metabolic effects.

BACKGROUND:  The metabolic effects of oral calcium (Ca) supplementation during plateletpheresis were evaluated in a randomized, placebo‐controlled trial.

Randomized placebo-controlled study of oral calcium carbonate administration in plateletpheresis: I. Associations with donor symptoms

BACKGROUND:  The effect of oral calcium (Ca) supplements in preventing citrate‐induced symptoms during plateletpheresis was evaluated in a randomized, blinded, placebo‐controlled trial.

Intracoronary infusion of autologous mononuclear cells from bone marrow or granulocyte colony-stimulating factor-mobilized apheresis product may not improve remodelling, contractile function, perfusion, or infarct size in a swine model of large myocardial infarction

AIMS In a blinded, placebo-controlled study, we investigated whether intracoronary infusion of autologous mononuclear cells from granulocyte colony-stimulating factor (G-CSF)-mobilized apheresis product or bone marrow (BM) improved sensitive outcome measures in a swine model of large myocardial infarction (MI). METHODS AND RESULTS Four days after left anterior descending (LAD) occlusion and reperfusion, cells from BM or apheresis product of saline- (placebo) or G-CSF-injected animals were infused into the LAD. Large infarcts were created: baseline ejection fraction (EF) by magnetic resonance imaging (MRI) of 35.3 +/- 8.5%, no difference between the placebo, G-CSF, and BM groups (P = 0.16 by ANOVA). At 6 weeks, EF fell to a similar degree in the placebo, G-CSF, and BM groups (-7.9 +/- 6.0, -8.5 +/- 8.8, and -10.9 +/- 7.6%, P = 0.78 by ANOVA). Left ventricular volumes and infarct size by MRI deteriorated similarly in all three groups. Quantitative positron emission tomography (PET) demonstrated significant decline in fluorodeoxyglucose uptake rate in the LAD territory at follow-up, with no histological, angiographic, or PET perfusion evidence of functional neovascularization. Immunofluorescence failed to demonstrate transdifferentiation of infused cells. CONCLUSION Intracoronary infusion of mononuclear cells from either BM or G-CSF-mobilized apheresis product may not improve or limit deterioration in systolic function, adverse ventricular remodelling, infarct size, or perfusion in a swine model of large MI.